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Abstract
Circulating tumor DNA (ctDNA) analysis has the potential to allow non-invasive analysis of
tumor mutations in advanced cancer. In this study we assessed the reproducibility of digital
PCR (dPCR) assays of circulating tumor DNA in a cohort of patients with advanced breast
cancer and assessed delayed plasma processing using cell free DNA preservative tubes.
We recruited a cohort of 96 paired samples from 71 women with advanced breast cancer
who had paired blood samples processed either immediately or delayed in preservative
tubes with processing 48–72 hours after collection. Plasma DNA was analysed with multi-
plex digital PCR (mdPCR) assays for hotspot mutations in PIK3CA, ESR1 and ERBB2, and
for AKT1 E17K. There was 94.8% (91/96) agreement in mutation calling between immedi-
ate and delayed processed tubes, kappa 0.88 95% CI 0.77–0.98). Discordance in mutation
calling resulted from low allele frequency and likely stochastic effects. In concordant sam-
ples there was high correlation in mutant copies per ml plasma (r2 = 0.98; p<0.0001). There
was elevation of total cell free plasma DNA concentrations in 10.3% of delayed processed
tubes, although overall quantification of total cell free plasma DNA had similar prognostic
effects in immediate (HR 3.6) and delayed (HR 3.0) tubes. There was moderate agreement
in changes in allele fraction between sequential samples in quantitative mutation tracking
(r = 0.84, p = 0.0002). Delayed processing of samples using preservative tubes allows for
centralized ctDNA digital PCR mutation screening in advanced breast cancer. The potential
of preservative tubes in quantitative mutation tracking requires further research.
Introduction
Circulating tumor DNA analysis has the potential to transform the treatment of cancer [1, 2].
Analysis of ctDNA has the potential to define the genetics of metastatic cancer in real time, and
identify changes in genetics have been selected by prior therapy [2–5]. In early cancer detection
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of ctDNA has the potential to identify patients with minimal residual disease post treatment to
identify which patients are at high risk of future relapse [6, 7].
Yet major challenges complicate the roll out of circulating tumor DNA into standard prac-
tice. An optimal assay should give the same result in repeat samples 100% of the time,
although this is hard to achieve in all assays including robust clinical assays such as ER, PR
and HER2 testing for breast cancer [8]. Few studies have assessed the reproducibility of
ctDNA analysis [9–14], a major constraint on multi-centre studies and ultimately clinical
adoption into using ctDNA as a diagnostic tool is the requirement under the current recom-
mended standard practice for processing, which utilizes EDTA tubes, to process samples
within hours of collection. This both adds potential variability in the processing of samples at
individual sites, and necessitates expensive shipping of frozen samples to central analysis cen-
ters. In fetal medicine preservative tubes, that prevent white blood cell lysis, are a widely used
standard of care, allowing samples to be shipped for central processing [15, 16]. Preliminary
studies have also suggested that preservative tubes may present an option for ctDNA assess-
ment [17].
Here we assessed the potential of preservative tubes for ctDNA in advanced breast cancer,
and through comparison of EDTA with preservative tubes we addressed the reproducibility of
ctDNA analysis.
Materials and Methods
Patient Cohort and Sample Collection
96 paired blood samples were obtained from 71 patients with metastatic breast cancer treated
at the Royal Marsden Hospital. All patients had recently progressed following prior therapy,
although patients were allowed to be takingmaintenance therapies such as hormone therapy
or trastuzumab at the time of plasma sampling. ER, PR, and HER2 were assessed in a single
laboratory at the Royal Marsden Hospital Histopathology department. A tumor was consid-
ered to be HER2 positive if 3+ positive by Hercept test, or 2+ positive with a FISH/SISHHER2:
CEP17 ratio of 2.2. All participants in the study provided ethically-approved written informed
consent in accordance to The Royal Marsden Hospital (RMH) guidelines that also dictate stor-
age. Research was approved by Bromley-London Research Ethics Committee reference REC
Ref No: 10/H0805/50 and the Royal Marsden Hospital Research REC Ref No: 11/LO1595.
(Table 1)
Blood samples were collected sequentially into a 10 ml EDTA K2 blood collection tube and
a 10 ml Streck Cell-Free DNA blood collection tube followingmanufacturer’s recommenda-
tions. Streck tubes were shipped on biological specimen containers at ambient temperature to a
central lab for processing. Tubes took between 48 and 72 hours to arrive at the central process-
ing lab and were processed once received.
Processing of plasma and extraction of cfDNA
Blood collected in EDTA K2 tubes was processedwithin two hours of sample collection,while
blood collected in Streck Cell-FreeDNA tubes was processed 48–72 hours after collection.
Bloodwas centrifuged at 1600 g for 20 minutes and plasma separated using air displacement
pipettes, leaving 0.25 ml above the buffy coat layer. Plasma was stored at -80°C until cfDNA
extraction. cfDNA was extracted from 2 ml of plasma using the QIAamp circulating nucleic
acid kit (Qiagen) according to the manufacturer’s instructions. The cfDNA was eluted into
50 μl buffer AVE and stored at -20°C as previously described [4, 18].
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Genomic DNA extraction from cell lines
Genomic DNA (gDNA) for dPCR was extracted from the following STR-typed PIK3CA
mutant cell lines: CAL-51 (c.1624G>A; p.E542K) breast carcinoma (Leibniz Institute
DSMZ-GermanCollectionof Microorganisms and Cell Cultures Cat no: ACC302), MCF7
(c.1633G>A; p.E545K) human breast adenocarcinoma (European Collectionof Cell Cultures
(ECACC) Cat no: 86012803), GP2d (c.3140A>T; p.H1047L) human colon adenocarcinoma
(European Collectionof Cell Cultures (ECACC) Cat no: 95090714) and MFM-223
(c.3140A>G; p.H1047R) human mammary carcinoma (European Collectionof Cell Cultures
(ECACC) Cat no: 98050130) with DNeasy Blood and Tissue Kit (Qiagen) as per manufacturer
instructions.DNA was quantified using Quant-iT PicoGreen dsDNA Assay Kit (Life Technol-
ogies) as per manufacturer instructions. 5 μg genomic DNA was restriction digested using Hin-
dIII endonuclease and 1ng was used for subsequent dPCR assays.
Quantification of cfDNA from plasma using dPCR
cfDNA isolated from plasma was quantified on a Bio-RadQX-200 droplet ddPCR using
RNase P and TERT as the reference genes as previously described [19]. 1 μl of eluate was
added to a dPCR reaction containing 10 μl ddPCR Supermix for probes (Bio-Rad). If the two
probes were used in duplex, 0.5 μl of TaqMan Copy Number Reference Assay, human, RNase
P (Life Technologies) and 1 μl of TaqMan Copy Number Reference Assay, human, TERT (Life
Technologies) on a total volume of 20 μl were added. If only one probe was used in uniplex,
1 μl of TaqMan Copy Number Reference Assay, human, RNase P (Life Technologies) or 1 μl
of TaqMan Copy Number Reference Assay, human, TERT (Life Technologies) on a total vol-
ume of 20 μl were added. The reaction was partitioned into ~14,000 droplets per sample in a
Table 1. Clinical and pathological characteristics of study patients.
n 71
median age 59
ER+ 85% (60)
PR + 52% (37)
HER2 + 19%(14)
Histological type
IDC 76% (54)
ILC 14% (10)
Other 10% (7)
site of metastasis
bone 41% (29)
brain 4% (3)
liver 18% (13)
lung 11% (8)
nodal 46% (33)
other site 25% (18)
number of metastatic sites
multiple sites 77% (55)
single site 23% (16)
ER + − positive for estrogen receptor, PR + positive for progesterone receptor, HER2 + − HER2 positive by
immunohistochemistry or by in situ hybridization, IDC—invasive ductal carcinoma, ILC—invasive lobular
carcinoma.
doi:10.1371/journal.pone.0165023.t001
Reproducibility of ctDNA Analysis
PLOS ONE | DOI:10.1371/journal.pone.0165023 October 19, 2016 3 / 12
QX-200 droplet generator according to manufacturer’s instructions. Emulsified PCR reactions
were run on a 96 well plate on a G-Storm GS4 thermal cycler incubating the plates at 95°C for
10 min followed by 40 cycles of 95°C for 15 sec and 60°C for 60 sec, followed by 10 min incu-
bation at 98°C. The temperature ramp increment was 2.5°C/sec for all steps. Plates were read
on a Bio-RadQX-200 droplet reader using QuantaSoft v1.6.6.03 software from Bio-Rad. At
least two negative control wells with no DNA were included in every run. The amount of
amplifiable DNA for RNase P and/or TERT were calculated using the Poisson distribution in
QuantaSoft.
Development of multiplex dPCR (mdPCR) assays and analysis of
cfDNA from plasma
mdPCR assays were developed and optimised by iterative rounds of varying concentrations of
the optimised uniplex primers and probes (S1 Table) in order to obtain discrete populations
for each of the mutations analysed by the assay. Assays were developed by using a combination
of either cell gDNA or synthetic DNA carrying the mutation of interest spiked into an other-
wiseWTDNA background. PCR cycling conditions for mdPCR assays were as described
above with annealing/extension temperatures as shown in S2 Table. Plates were read on a Bio-
Rad QX-200 droplet reader using QuantaSoft v1.6.6.03 software from Bio-Rad to assess the
number of droplets positive for mutant DNA, wild type DNA, both or neither. At least two
negative control wells with no DNA were included in every run.
For AKT1 (c.49G>A; E17K) we used two Bio-Rad commercially available assays (E17K:
dHsaCP2000031, FAM-labelled andWT: dHsaCP2000032, HEX-labelled). These assays were
used in a duplex dPCR following manufacturer’s recommendations (S2 Table).
mdPCR analysis
Since QuantaSoft v1.6.6.03 software does not have the functionality to analyze multiplex assays
data, and in order to assess mutation fraction, the multiplex plots were revised to manually
gate in or out the desired populations to be analysed. This was done reiteratively to analyze all
the desired populations present on a plot.
Once a desiredmutant andWT populations had been gated in, the concentration of mutant
DNA (copies of mutant DNA per droplet) was estimated from the Poisson distribution. Num-
ber of mutant copies per droplet Mmu = -ln (1-(nmu/n)), where nmu = number of droplets
positive for mutant-FAM probe and n = total number of droplets. The DNA concentration in
the reaction was estimated as follows MDNAconc = -ln (1-(nDNAcon/n)), where nDNAconc =
number of droplets positive for mutant-FAM probe and/orWild Type-VIC probe and n = total
number of droplets. The FractionMutation = Mmu/ MDNAconc.
To assess the number of mutant copies per ml of plasma, the number of mutant-FAM posi-
tive droplets was adjusted for the number of wells run for the sample, the total number of drop-
lets generated, the median volume of a droplet (0.89pl), and volume equivalent of plasma run,
using the following formula:
Mutant copies per ml = (Total number of droplets positive for FAM) x 20,000 x (number of
wells run/volume of plasma equivalents) / (total number of droplets generated0.89)
A mutation was only considered to be present if two or more FAM positive droplets were
detected in 0.5 ml plasma equivalent DNA, with this criterion for a positive test being pre-
defined. In addition, PIK3CAmutations called by multiplex were validated using the uniplex
assay for the calledmutation. Mutant allele fraction and mutant copies/ml were calculated as
for the multiplex assay.
Reproducibility of ctDNA Analysis
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Statistical analysis
All statistical analysis was performedwith GraphPad Prism version 6.0 and Microsoft Excel.
All p values are two sided and considered significant if p<0.05. Error bars represent SEM of
three experiments.
Results
Quantification of cfDNA from Plasma using digital PCR on immediately
processed and delayed blood collection tubes
To compare the total amount of cfDNA in samples processed immediately or delayed using pre-
servative tubes, we assessedDNA quantification using RNAse P and TERT, two commercially
available copy number assays, on an independent set of 46 plasma samples frommetastatic
breast cancer patients (S1 Fig). Since we found TERT to report slightly higher concentrations of
cfDNA when comparing the two assays, we subsequently used RNAse P only in this study. We
quantified total cfDNA using RNase P in a cohort of 96 paired blood samples from immediately
processed EDTA blood tubes and Streck Cell-FreeDNA tubes delayed 48/72 hours post veni-
puncture (Fig 1A and 1B). Correlation on the total amount of cfDNA detected between the two
tubes (Fig 1A) and Bland-Altman comparison of the two processingmethods suggested
increased total free DNA concentrations in some samples collected in the delayed processed
Streck samples (p = 0.0144 Student’s one sample t test, Fig 1B). Taking immediately processed
EDTA blood collection tubes as the recommended standard practice, 28/96 (29.1%) (range
178.84–0.13, median 1.17 ng cfDNA per ml of plasma) pairs had greater than a 2-fold increase
in cfDNA detected in the Streck Cell-FreeDNA blood collection tube as compared to the EDTA
blood collection tube. Furthermore, 10/96 (10.3%) pairs had a greater than 10-fold increase in
the amount of cfDNA detected between the two tubes suggesting possible white blood cell lysis
and subsequent release of gDNA on these tubes. Two of these pairs had either a mutation on
PIK3CA or ESR1. Analysis of the allele frequency or the number of mutant copies per ml
revealed a decrease of both on the Streck blood collection tube (BCT) as compared to the EDTA
BCT (S1 Fig).
We assessed the impact of potential WBCDNA release on prognostication of total cell free
plasma DNA (plasma DNA) concentration, comparing patients with high plasma DNA con-
centration above the upper quartile to those with plasma DNA concentrations below the upper
quartile. High plasma DNA concentration had a worse prognosis both in immediate (Fig 1C,
HR 3.4 95% CI 2.5 to 14.7, p = 0.0002 Log rank test) and delayed samples (Fig 1D, HR 3.0 95%
CI 2.0 to 11.0, p = 0.001). Therefore both immediate and delayed processing had a similar pre-
dictive power, although 6 patients (8%) with plasma DNA concentration below the upper quar-
tile in immediate processed samples had elevated plasma DNA in their corresponding delayed
processed samples.
Assessment of mutation detection by mdPCR in immediate and delayed
processed samples
To detect circulating tumor DNA in delayed versus immediate processed samples we usedmul-
tiplex digital PCR assays (S2 Fig and S2 Table). Assays were performed on 0.5 ml plasma equiv-
alent volume. There was high agreement betweenmultiplex and uniplex PIK3CA assays (S3
Fig). Agreement betweenmultiplex and uniplex ESR1 assays had been previously shown [4].
We investigated the performance of mdPCR assays on cfDNA extracted from the cohort of
96 pairs of plasma samples processed immediately or delayed. We detected one or more muta-
tions on 43.8% of the pairs (42/96), detecting 62 mutations in these 42 pairs. The agreement in
Reproducibility of ctDNA Analysis
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mutation calling on cfDNA between the EDTA tube and the Streck tube was 94.8% (91/96,
kappa 0.88 95% CI 0.77–0.98, Fig 2A). Two PIK3CA pairs were discordant, both with alleles
frequencies below 0.01. Three pairs had discordant ESR1mutations, again with very low fre-
quency detected in two cases (<0.01) and in one case with a mutation frequency close to 0.1 as
true discordant case. Discordance was more likely to occur at low allele frequencies (Fig 2B).
With evidence of higher total cfDNA in delayed Streck versus immediate EDTA we com-
pared allele frequencywith mutant copies per ml plasma as two related but distinct assessments
of mutation abundance. There was very high correlation in mutation allele frequency between
delayed and immediate tubes (r2 = 0.94; p<0.0001, Pearson’s correlation coefficient, Fig 2C),
There was even higher correlation for copies of mutant allele per ml of plasma (r2 = 0.98;
Fig 1. Comparison of total free plasma DNA levels between immediate processed EDTA samples and delayed processed
Streck samples. A. Correlation plasma DNA levels of immediate processed EDTA samples and delayed processed Streck samples.
Pearson correlation coefficient. B. Bland-Altman plot of data in part A with dashed lines representing 95% CI. C. Overall survival with
plasma DNA quantified in immediate EDTA tubes divided on high plasma DNA levels above the upper quartile versus low plasma DNA
below the upper quartile. Log rank test with hazard ratio (HR) and 95% confidence intervals (95% CI). D. Overall survival with plasma
DNA quantified in delayed Streck tubes divided on high plasma DNA levels above the upper quartile versus low plasma DNA below the
upper quartile. Log rank test with hazard ratio.
doi:10.1371/journal.pone.0165023.g001
Reproducibility of ctDNA Analysis
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p<0.0001, Pearson’s correlation coefficient, Fig 2D), which likely indicated the higher ability of
this quantification method to take into account possible contamination by gDNA released
from white blood cells.
The highest number of mutations detectedwas in PIK3CA (22.9%, 22/96) and ESR1 (18.7%,
18/96). Only two pairs had an AKT1mutation (2.1%), while no mutations were detected for
Fig 2. Agreement in mutation calling between immediate EDTA and delayed Streck tubes. A. Contingency table for mutation detection
on immediately processed tubes versus delayed processing tubes,. B. Scatter plot of mutation allele frequency in concordant vs discordant
samples. Mann Whitney U test. C. Correlation of mutational allele frequent frequency on immediate and delayed processing tubes. Pearson
correlation coefficient. D. Correlation of mutant copies per ml of plasma in immediate and delayed processing tubes. Pearson correlation
coefficient.
doi:10.1371/journal.pone.0165023.g002
Reproducibility of ctDNA Analysis
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ERBB2 (Fig 3A). Out of the 22 mutations detected on PIK3CA, the highest incidence was on
substitution H1047R (c.3140A>G) in line with previous published work (Fig 3B). For ESR1
the highest prevalence of mutations detectedwas at position D538G (c.1613A>G) on the LBD
(83.3%, 15/18 pairs) (Fig 3C), with most of the mutations detected on this cohort were of poly-
clonal nature (78%, 14/18 pairs) with two or mutations on 35.7% (5/14) of the cases and two
ESR1mutations on 28.6% (4/14) of the pairs. In one patient we detected a PIK3CA and an
ESR1mutation in the same sample.
Mutation tracking on immediately processed tubes versus delayed
tubes
Changes in circulating tumor DNA abundance may be used to predict sensitivity and resis-
tance to therapy. We assessed whether delayed processed tubes gave similar performance to
immediate processed tubes. For 6 patients, with one or more mutations detected, we had
sequential samples taken longitudinally along the study. This provided us with an opportunity
to track mutational abundance on the two differentially processed tubes and assess the repro-
ducibility and performance of the delayed tubes. There was moderate agreement in change in
copies per ml and mutation allele frequency (S4 Fig) between immediate and delayed samples
for serial blood samples. For fractionmutant the regression coefficientwas r = 0.85 with a
slope of 1.11 (95% CI 0.66 to 1.55, p = 0.0002, linear regression). For copies per ml the regres-
sion coefficientwas r = 0.84 with a slope of 0.78 (95% CI 0.44 to 1.12, p = 0.0003, linear
regression).
Discussion
Here we describe the analytical validity and reproducibility of mdPCR ctDNA analysis for clin-
ical diagnosis of targetable hotspot mutations in advanced breast cancer. We show that
mdPCR ctDNA analysis is highly reproducible for mutation detection, although reproducibil-
ity is modestly limited in the detection of low abundance mutations. We show that shipping
samples at room temperature in Streck preservative tubes for central processing and analysis is
a viable alternative to immediate sampling for mutation detection. Consequently this would
facilitate centralized testing for multi-center trials and routine clinical adoption.
Fig 3. Mutation frequency observed in advanced breast cancer. A. Mutation frequency observed in plasma of patients with advanced cancer.
Only samples with concordant mutations in both samples are assessed as having a mutation. Individual mutations observed for B. PIK3CA and C.
ESR1 mutations detected.
doi:10.1371/journal.pone.0165023.g003
Reproducibility of ctDNA Analysis
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Although digital PCR is a highly sensitive technique for rare mutation detection, it has been
limited in clinical use through detection of a single mutation per assay approach. We show that
up to 4 mutations can be multiplexed into a single assay, allowing screening of multiple muta-
tions in samples with limited amount of material. This overcomes the major limitation allow-
ing screening for a large number of hotspot mutations from each sample.
Whilst our data demonstrate that shipping of samples in preservative cell free DNA Streck
tubes preserves the total amount of circulating tumor DNA, we demonstrate that in a small
number of samples there is elevated total DNA in the Streck tube compared to immediately
processed samples, likely reflecting a low level of WBC lysis does occur in a small number of
samples. There was no indication during plasma processing which tubes were subject to
increasedwhite blood cell lysis and haemolysis did not indicate higher cfDNA levels. In addi-
tion increasedWBC lysis was not linked to level of cfDNA in the sample indicating that
increasedWBC lysis in a particular tube was likely associated with the way the bloodwas
mixed with the preservatives on the tube. The level of WBC lysis and release of high molecular
weight germlineDNA did not affect the sensitivity of ctDNA analysis by digital PCR. However,
in assays such as ctDNA sequencing, which are less sensitive for low allele frequencies, this
could reduce sensitivity. Potentially a level of WBC contamination in some samples may
reduce sensitivity bringing real mutations into the range of noise generated during sequencing
arising from events such as DNA polymerase error, unless error-correction techniques are
employed to take account of this [20].
We show that mutation tracking assessed by both allele fraction and copies per ml shows
modest agreement between immediate and delayed samples, with no evidence of systematic
bias in the slope of the agreement (Fig 4). However, the degree of variability observed in our
study suggests that delayed processed tubes are likely to be viable to detect large fold changes in
ctDNA abundance, but may potentially be limited in the robust detection of small changes in
abundance. In assessing change in abundance it is unknown if change in allele frequency or
Fig 4. Agreement in change in mutation abundance in sequential samples between immediate EDTA and delayed Streck samples. A.
Agreement in fold change in mutation allele frequency between immediate and delayed samples in sequential samples from 6 patients (r = 0.85,
p = 0.0002). B. Agreement in fold change in mutant copies per ml between immediate and delayed samples in sequential samples from 6 patients
(r = 0.84, p = 0.0003).
doi:10.1371/journal.pone.0165023.g004
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mutant copies per ml of plasma has higher discriminatory power. Further research in this area
is required.
Our study suggests that shipping samples at room temperature to a central facility could
become a new gold standard where the sample is to be analysed by digital PCR for mutation
identification. Such analysis will allow fast and relatively cost effective analysis of tumor muta-
tions status that will facilitate trials of rare and acquired mutations in cancer.
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S1 Fig. Comparison of assays for circulating freeDNA quantification from plasma.A.
Optimization of dPCR assays to quantify cfDNA on plasma. B. Correlation of plasma DNA
measurements with two different reference assays. C. Samples with a>10 fold increase in
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